AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients

CAR-T Digest - August 2020

10 Sep 2024: AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients

Datopotamab deruxtecan demonstrated greater overall survival compared to docetaxel chemotherapy in the TROPION-Lung01 trial for NSCLC patients
The Phase III trial included 590 adults with advanced or metastatic NSCLC, and results were presented at the 2024 World Conference on Lung Cancer (WCLC)
A significant mean improvement of 2.3 months (14.6 months with the ADC versus 12.3 months with chemotherapy) in overall survival was noted in the nonsquamous disease subgroup with Datopotamab deruxtecan
Previous results showed improved progression-free survival with this drug, and Daiichi Sankyo and AstraZeneca have advanced it in over 20 trials
EMA approved Datopotamab deruxtecan for treating nonsquamous NSCLC and HER2-negative breast cancer in March 2024, with a US FDA decision expected by 20 December 2024